Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 6, Pages e002568
Publisher
BMJ
Online
2021-06-03
DOI
10.1136/jitc-2021-002568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
- (2020) Anthony R. Cillo et al. IMMUNITY
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
- (2020) Renata Ferrarotto et al. CLINICAL CANCER RESEARCH
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
- (2020) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
- (2020) Michael G McCusker et al. OncoTargets and Therapy
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
- (2020) Ravindra Uppaluri et al. CLINICAL CANCER RESEARCH
- The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A systematic review
- (2020) Stephanie Y. Chen et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- Molecular genetics of head and neck squamous cell carcinoma
- (2019) Esma Saada-Bouzid et al. CURRENT OPINION IN ONCOLOGY
- Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response
- (2019) J E Stein et al. ANNALS OF ONCOLOGY
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
- (2019) Julie E Stein et al. CLINICAL CANCER RESEARCH
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
- (2018) M T Tetzlaff et al. ANNALS OF ONCOLOGY
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- A snapshot of the evolving epidemiology of oropharynx cancers
- (2018) Anil K. Chaturvedi et al. CANCER
- Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer
- (2018) Alex K Bryant et al. JNCI-Journal of the National Cancer Institute
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- Prognostic Role of p16 in Nonoropharyngeal Head and Neck Cancer
- (2018) Alex K Bryant et al. JNCI-Journal of the National Cancer Institute
- T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
- (2018) Benjamin A. Kansy et al. OncoImmunology
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Increased PD-1 + and TIM-3 + TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
- (2017) Hyun-Bae Jie et al. Cancer Immunology Research
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
- (2015) Hyun-Bae Jie et al. CANCER RESEARCH
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer
- (2012) Maura L. Gillison et al. JOURNAL OF CLINICAL ONCOLOGY
- p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency
- (2011) Adel K. El-Naggar et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
- (2011) Anil K. Chaturvedi et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
- (2010) K. Kian Ang et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started